SOA Wealth Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

SOA Wealth Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-801	Closed	-$29.8K	–	978
2023 Q1	$29.8K	Hold	801	–	–	0.01%	355
2022 Q4	$36.3K	Hold	801	–	–	0.01%	318
2022 Q3	$55K	Buy	+801	New	+$59.3K	0.02%	251
2022 Q2	–	Sell	-801	Closed	-$65K	–	1066
2022 Q1	$65K	Buy	801 +401	+100%	+$41K	0.02%	276
2021 Q4	$59K	Sell	400 -401	-50%	-$62.3K	0.01%	276
2021 Q3	$141K	Hold	801	–	–	0.04%	191
2021 Q2	$129K	Hold	801	–	–	0.03%	196
2021 Q1	$137K	Hold	801	–	–	0.04%	166
2020 Q4	$164K	Buy	+801	New	+$173K	0.04%	146

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SOA Wealth Advisors's MRTX Position: Q2 2023 in Review

SOA Wealth Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 801 shares — an estimated $29.8K sold.

SOA Wealth Advisors first reported a position in MRTX in Q4 2020 and held it in 9 quarters. The position peaked at $164K in Q4 2020. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

SOA Wealth Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
SOA Wealth Advisors sold 801 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $29.8K.
SOA Wealth Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
SOA Wealth Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $164K in Q4 2020.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on SOA Wealth Advisors's 13F filing for Q2 2023, filed 7 Jul 2023.